Introduction
============

As the goal of asthma therapy is to maintain long-term control using the smallest amount of medication possible, current asthma guidelines recommend consideration of stepping-down therapy if asthma remains well controlled for at 3 months to reach a minimum effective dose.[@b1-ppa-10-339],[@b2-ppa-10-339] To our knowledge, based on the data from a systematic review, asthma exacerbations were statistically no more likely among individuals who reduced inhaled corticosteroids (ICSs) compared to those who maintained their ICS dose.[@b3-ppa-10-339] In addition, it has been reported that stepping-down asthma medication is frequently successful, almost 60%--70%.[@b4-ppa-10-339],[@b5-ppa-10-339]

A clear plan of care and follow-up is needed when stepping-down ICSs, because some patients are likely to have recurrent exacerbations.[@b6-ppa-10-339] Some factors of severity,[@b7-ppa-10-339] uncontrolled asthma, airway limitation,[@b8-ppa-10-339] and previous exacerbations in a previous year[@b9-ppa-10-339] were predictors of future risks of exacerbations. However, little is known about which factors are associated with decisions to stepping-down of ICSs in asthma. Few reports demonstrated that predictors of recurrence of asthma symptoms after withdrawal of therapy in mild persistent asthmatics were older age[@b10-ppa-10-339],[@b11-ppa-10-339] and longer disease duration.[@b10-ppa-10-339]

We, therefore, conducted a study to develop and validate a simplified clinical prediction score for estimating the likelihood of failed stepping-down of ICSs in patients with adult asthma who have maintained asthma control for ≥3 months. The scores would aid general practice physicians in identifying individuals who are at likelihood of failed stepping-down of ICSs and should have further investigation and management.

Methods
=======

Patients
--------

One hundred and twenty-six eligible patients were recruited from three hospitals in Sanin area in the western side of Japan. The diagnosis of asthma was made on the basis of the Global Initiative for Asthma (GINA) guideline.[@b2-ppa-10-339] Participants were required to be aged 20 years and above, have a diagnosis of persistent mild-to-moderate asthma for at least 3 months, be clinically stable, currently treated with ICSs or combination of ICS/long-acting bronchodilator agonist (LABA), and have features of controlled asthma, which are defined in the following manner: a score on the Asthma Control Questionnaire (ACQ) of \<1.5.[@b12-ppa-10-339] Those patients satisfying any of the following criteria were excluded: a diagnosis of chronic obstructive pulmonary disease, as defined by the Global Initiative for Chronic Obstructive Lung Disease guidelines;[@b13-ppa-10-339] a history of near fatal asthma; oral steroid in the preceding 3 months; aspirin intolerance; flow expiratory volume in 1 second (FEV~1~) ≤50% predicted; pregnancy; recurrent lower respiratory tract infections; and the presence of concomitant respiratory disease such as bronchiectasis. The study was approved by the Yonago Medical Centre Committee on Medical Ethics (24-7), and all participants gave written informed consent. The protocol was registered under UMIN 000011565 in the clinical trial registry.

Data accumulation
-----------------

We assessed the following characteristics of patients: age, sex, age of onset of asthma, self-reported smoking (never, former, and current), type of onset symptoms (cough-predominant asthma or wheezing-predominant asthma), need for emergency visits or steroid bursts in the last year, comorbid diseases of rhinitis/rhinosinusitis, IgE value, and IgE specific for aeroantigens.

Asthma severity was characterized using asthma of severity (AOS) score.[@b7-ppa-10-339],[@b14-ppa-10-339] The AOS score ranges from 0 to 28, with higher scores indicating more severe asthma.

Rhinitis and rhinosinusitis were diagnosed according to symptom-based definition according to the Allergic Rhinitis and its Impact on Asthma[@b15-ppa-10-339] and European Position Paper of Rhinosinusitis and Nasal Polyps guidelines.[@b16-ppa-10-339]

Pulmonary function measurements included prebronhchodilator flow expiratory volume in 1 second (pre-FEV~1~) and postbronchodilator FEV~1~ (post-FEV~1~). All pulmonary function measurements at eligibility were expressed as the percentage predicted for a Japanese population, which was calculated using the formula proposed by the Japanese Respiratory Society.[@b17-ppa-10-339]

Adherence is measured as the sum of drug supply days between first and last fill dates divided by length of drug therapy.[@b18-ppa-10-339]

Assessment of phlegm grade is based on the Leicester Cough Questionnaire (LCQ), according to the question, "In the last 2 weeks, have you been bothered by sputum (phlegm) production when you cough?" A seven-point Likert scale was used throughout the development of the LCQ ranging from 1 to 7: 1= every time, 2= most times, 3= several times, 4= some times, 5= occasionally, 6= rarely, and 7= never.

Protocol of stepping-down
=========================

In all of the eligible patients, asthma symptoms have been well controlled for 3 or more months. According to GINA guideline,[@b2-ppa-10-339] stepping-down treatment occurred upon agreement between patient and each respiratory professional, with full discussion of potential consequences including reappearance of symptoms and increased risk of exacerbations. A strategy for reducing ICSs dose was performed according to the following GINA recommendation listed below: When ICSs had been used alone in medium-to-high doses, a 50% reduction in dose was attempted.Where control had been achieved at a low dose of ICS alone, treatment was switched to once-daily dosing.When asthma had been controlled with a combination of ICS and LABA, dose reduction of ICSs to 50% was started while continuing the LABA.

Outcome for this study is failure of stepping-down, judged as occurring exacerbation, which is defined as events where symptoms worsen enough to require a change in treatment.[@b19-ppa-10-339]

Statistical analysis
--------------------

Comparison between groups was done using the *χ*^2^-statistics, Mann--Whitney *U*-test, and Student's *t*-test. Nelson--Aalen plot of the cumulative hazard, log-rank test, and logistic regression analysis were conducted with R (R Development Core Team 2015). Results are reported as mean (SD), ranges, or percentages of the appropriate denominator. Significance was accepted at the 5% level.

Logistic regression analysis was used to determine the relationship between the variables and failed stepping-down. Variables with *P*\<0.2 in univariate model were considered significant and were entered into the multivariate model. With an expected failed stepping-down rate of 40%, we required 120 attempts (48 failures) to approximately perform multivariate logistic regression with five variables. In the multivariate model, variables with *P*≤0.05 were considered significant. The final model was obtained with multivariate logistic regression and submitted to internal validation with leave-one-out analysis. Model's performances of the final model measured by the goodness-of-fit statistic and the area under the curve (AUC) were assessed. The Hosmer--Lemeshow test is a statistical test for goodness of fit for logistic regression models. A risk score was created using the β coefficients of logistic regression model. Individuals were allocated scores relevant to each variable and summed up.

For analysis of time-to-failure, time-to-first occurrence of failure of stepping-down was calculated from start of stepping-down until exacerbations, patients were considered as censored at the end of stepping-down. Risk of occurrence of failure of stepping-down over time was displayed using Kaplan--Meier and Nelson--Aalen curves.[@b20-ppa-10-339]

Results
=======

Patients
--------

[Table 1](#t1-ppa-10-339){ref-type="table"} lists the general characteristics of patients at the time of starting stepping-down of ICSs. In the eligible 126 patients who were enrolled, all were well controlled as graded on the basis of ACQ (0.05±0.15). Of the patients with follow-up, 29 (23.0%) were identified from failed stepping-down attempts. Of the 29 failed stepping-down attempts, all were judged to need to return to the previous ICS dose due to loss of asthma control. Two needed steroid bursts, but none required hospitalization and emergency care. There was no significant difference in the serum house-dust-mite-specific IgE levels between the two groups. When adherence was measured as the sum of drug supply days between the first and last fill dates divided by the length of drug therapy, there was no significant difference between the two groups.

Predictors for failed stepping-down
-----------------------------------

All variables with *P*-values \<0.2 were simultaneously included in a multivariate model, as listed in [Table 2](#t2-ppa-10-339){ref-type="table"}. The final model contained only two variables (ie, comorbidity with rhinitis/rhinosinusitis and phlegm grade), and their odds ratio (ORs) are listed in [Table 2](#t2-ppa-10-339){ref-type="table"}. The scoring scheme for each variable was constructed by rounding off the ORs and assigning 1 to the reference category. A total score of 2 demonstrated the score discriminative ability as 0.77 of AUC. The goodness of fit was assessed, and it was found that the final model was fit well with our data (the Hosmer--Lemeshow test, *P*=0.264).

When the two variables were added to form the prediction score, the AUC was 0.75 (range: 0.62--0.88) for naïve prediction and 0.72 (range: 0.60--0.86) after cross-validation. The *C* statistics of the derivative and validated models were very much similar, ie, 0.75 and 0.72. The average difference (known as degree of optimism) was 0.03. Hence, this analysis allows to rule out substantial overfitting of the prediction score.

When the scores for failure rate were compared, failure of stepping-down attempts occurred in 4 of 44 (9%) patients with "Score 0", 9/51 (18%) with "Score 1", and 16/31 (52%) with "Score 2".

For analysis of time to failure, the average of duration of follow-up was 13 months (7--1,037 days); 108±90 days (7--379 days) for the failed patients; and 413±220 days (78--1,037 days) for the patients who ultimately succeeded in their stepping-down attempts. Among each score, total score as 2 is shown as higher risk of failed stepping-down in Kaplan-Meier curve ([Figure 1A](#f1-ppa-10-339){ref-type="fig"}). The risk of failed stepping-down also can be interpreted in terms of cumulative hazard curve, which graphically displays the risk experienced over the entire follow-up period. As shown in [Figure 1B](#f1-ppa-10-339){ref-type="fig"}, visual inspection of the Nelson--Aalen curve reveals that cumulative hazard ratio of failed stepping-down has been fixed at 1 year after stepping-down.

Discussion
==========

We have developed and validated a simplified clinical prediction score for failed stepping-down of ICSs in patients with controlled asthma. The scoring was made easier and more simplified as it used factors that were readily available and were simple to assess even in clinical practice.

In this study, approximately 70% of patients with controlled asthma could step-down ICSs according to the current guidelines. Our results are in accordance with Leuppi's report that determined that the majority of patients could undergo a halving of their ICS dose without exacerbation.[@b11-ppa-10-339] We mainly focus on estimating likelihood of failed stepping-down of ICSs. In our study, the predictors of failed stepping-down were comorbidity with rhinitis/rhinosinusitis and degree of sputum. In addition, we have validated the clinical prediction score using a leave-one-out technique, which is considered a good technique for internal validation.[@b21-ppa-10-339] The AUC of the simplified score was fair in both derivative and leave-one-out validated data (ie, 0.75 and 0.72), indicating that the score can discriminate well between individuals who were successful and those who failed. Our model is simplified and should be easy to apply in clinical practice because the required variables are routinely measured.

Our results that comorbidity with rhinitis/rhinosinusitis and phlegm grade might contribute to be failure of stepping-down of ICSs have been predictable, because some reports have shown that these variables were useful tools for predicting exacerbation. It was reported that patients with rhinitis/rhinosinusitis had increased asthma exacerbations.[@b22-ppa-10-339] In addition, chronic mucus hypersecretion that is characterized with chronic cough and sputum production occurs frequently in adults with stable asthma and is associated with more exacerbations in never smokers.[@b23-ppa-10-339] The reason that severity of asthma and lung function was not predictor of stepping-down failure might be explained by degree of severity. Our eligible patients with asthma were totally controlled and had low severity score of asthma.

Biomarkers evaluated for controlled condition of asthma included methacholine airway hyperresponsiveness,[@b24-ppa-10-339] sputum eosinophils,[@b25-ppa-10-339] and exhaled nitric oxide.[@b26-ppa-10-339],[@b27-ppa-10-339] While these approaches have shown promise in reducing exacerbations and/or improving asthma control, although performed in many subspecialty practices and research centers, they are not routinely available in most primary care practices.

Our results of treatment-to-failure analysis demonstrated that no exacerbations with halving ICSs for 1 year might suggest stable conditions of asthma. ICS treatment may be stopped if the patient remains well controlled on the lowest dose of ICS for 1 year according to GINA guideline.

There are some limitations in this report. First, an intrinsic limitation of our study design is that we could not confirm that patients were on the minimum does that maintained asthma control before study start. Thus, the overtreatment quite commonly reported in real-life conditions[@b28-ppa-10-339],[@b29-ppa-10-339] cannot be excluded. However, patients were selected from pulmonary centers where they were regularly assessed and treated according to the current guidelines, suggesting that the dose of the original ICS/LABA prescription was appropriate. The second limitation is the sample size. A larger sample size would have allowed more power to analyze the subgroup of responders that halve ICSs; therefore, we cannot exclude that lung function may be an important factor in decisions to step-down ICSs. Despite these limitations, we have preliminary evidence that having our prediction score may be important for patients and providers who are deciding on stepping-down of ICSs. As this study was performed retrospectively, future work will be necessary using a prospective design including external validation.

Our results demonstrated that reducing the dose of ICSs by 50% appears to be the safest method of stepping-down in accordance with the guidelines. We propose a simple clinical prediction score of failed stepping-down of ICSs.
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###### 

Baseline demographics and clinical characteristics of patients included in analyses

                                                             Total (n=126)   Success of stepping-down (n=97)   Failure of stepping-down (n=29)   *P*-value
  ---------------------------------------------------------- --------------- --------------------------------- --------------------------------- -----------
  Age, yr                                                    54.3±16.3       55.4±17.1                         51.3±13.9                         0.11
  Sex, % female                                              73              68                                90                                0.03
  Duration of asthma, yr                                     9.6±13.1        11.7±14.5                         3.7±3.8                           0.07
  BMI                                                        22.4±3.7        22.5±3.6                          22.3±4.0                          0.78
  Cough predominant, %                                       33              26                                55                                0.02
  Rhinitis/rhinosinusitis, %                                 15              11                                30                                0.002
  Family history of asthma                                   35              31                                50                                0.12
  Smoking status                                                                                                                                 
   Smoker/ex-smoker/no                                       8/23/95         7/20/70                           1/3/25                            0.46
  IgE, IU/L                                                  367±972         450±1,119                         133±141                           0.16
  FEV~1~, %predicted                                         94.0±19.4       92.6±19.9                         97.9±18.0                         0.48
  SOA                                                        5.3±2.6         5.2±2.5                           5.6±2.9                           0.93
  Phlegm grade                                               5.8±1.2         5.9±1.1                           5.4±1.6                           0.07
  Adherence                                                  0.85±0.24       0.90±0.16                         0.88±0.19                         0.21
  Dosage of ICSs[a](#tfn2-ppa-10-339){ref-type="table-fn"}                                                                                       0.24
   High dose, n (%)                                          22 (18)         17 (18)                           5 (20)                            0.97
   Moderate dose, n (%)                                      67 (53)         55 (57)                           12 (40)                           0.15
   Low dose, n (%)                                           37 (28)         25 (25)                           12 (40)                           0.11
  Type of ICSs                                                                                                                                   0.44
   Fluticasone, n (%)                                        72 (57)         56 (58)                           16 (55)                           0.81
   Budesonide, n (%)                                         47 (37)         37 (38)                           10 (34)                           0.72
   Beclomethasone HFA, n (%)                                 7 (6)           4 (4)                             3 (11)                            0.20
   Combination therapy, n (%)                                93 (73)         61 (63)                           22 (76)                           0.20
  Types of LABAs                                                                                                                                 0.12
   Salmeterol, n (%)                                         57 (61)         44 (72)                           13 (59)                           0.96
   Formoterol, n (%)                                         26 (39)         17 (28)                           9 (41)                            0.45
  Other antiasthmatics                                                                                                                           
   Antileukotrienes, n (%)                                   11 (9)          7 (7)                             4 (14)                            0.28
   Nasal steroids, n (%)                                     9 (8)           5 (5)                             4 (14)                            0.21

**Notes:** Unless otherwise stated values are mean ± SD.

ICS dose and dose equivalence were classified according to the BTS guidelines[@b30-ppa-10-339] as 1) high dose (≥800 μg/d beclomethasone (BDP) equivalent); 2) moderate dose (400--800 μg/d BDP); 3) low dose (\<400 μg/d BDP) and dose equivalence for BDP:budesonide at a 1:1 ratio and BDP:fluticasone at a 2:1 ratio.

**Abbreviations:** BMI, body mass index; FEV~1~, forced expiratory volume in 1 second; HFA, hydrofluoroalkane; ICSs, inhaled corticosteroids; LABAs, long-acting bronchodilator agonists; SOA, severity of asthma; yr, years.

###### 

Factors associated with successful stepping-down of ICSs and creating a scoring scheme: multiple logistic regression analysis

  Variables                                Coefficient   SE     OR (95% CI)         *P*-value   Scoring score for individual
  ---------------------------------------- ------------- ------ ------------------- ----------- ------------------------------
  Sex: female                              −0.76         0.90   0.47 (0.08--2.72)   0.40        0
  Duration of asthma: 7 years or more      −0.12         0.68   0.89 (0.23--3.35)   0.86        0
  Type: cough predominant                  −0.59         0.66   0.55 (0.15--2.01)   0.37        0
  Family history of asthma: yes            0.68          0.65   1.97 (0.55--7.09)   0.30        0
  Phlegm grade: 5 or less (occasionally)   −1.13         8.50   0.32 (0.09--0.98)   0.04        1
  Comorbidity: rhinitis/rhinosinusitis     −1.30         3.81   1.27 (0.07--0.97)   0.04        1

**Abbreviations:** CI, confidence interval; ICSs, inhaled corticosteroids; OR, odds ratio; SE, standard error.
